Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

173

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Overactive Bladder

Interventions

DRUG

Tolterodine

Extended release tolterodine tartrate 4 mg, once daily, for 1 months

DRUG

Tolterodine

Extended release tolterodine tartrate 4 mg, once daily, for 3 months

DRUG

Tolterodine 6

Extended release tolterodine tartrate 4 mg, once daily, for 6 months

Trial Locations (4)

Samsung Medical Center, Irwon-dong

Holy Family Hospital, The Catholic University of Korea, Gyeonggi-do

Asan Medical Center, Ulsan College of Medicine, Seoul

Seoul National University Hospital, Seoul